Literature DB >> 28743113

Pulmonary Hypertension in a Large Cohort with Hereditary Hemorrhagic Telangiectasia.

Veronique Vorselaars1, Sebastiaan Velthuis, Marco van Gent, Cornelis Westermann, Repke Snijder, Johannes Mager, Martijn Post.   

Abstract

BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is a vascular disorder characterized by arteriovenous malformations in the brain, liver, and lungs. Pulmonary hypertension (PH) is increasingly recognized as a severe complication of HHT. However, there are no studies describing the prevalence of PH in HHT compared to HHT-negative controls.
OBJECTIVE: To assess the estimated prevalence of PH in patients with HHT compared to HHT-negative controls.
METHODS: All consecutive subjects screened for HHT with available genetic testing and echocardiography-based peak tricuspid regurgitation velocity (TRV) measurement were included. Increased-probability PH was defined as a TRV >2.8 m/s.
RESULTS: In 578 subjects, both echocardiography and genetic testing were available. A reliable TRV was measured in 383 (66.3%), of whom 127 had HHT type 1 (HHT1), 150 had HHT type 2 (HHT2), and 106 were HHT-negative controls, with a mean TRV of 2.3 ± 0.4, 2.4 ± 0.5, and 2.2 ± 0.3 m/s, respectively (p = 0.008 and p < 0.001 vs. controls). Increased-probability PH was found in 42 subjects (8.7% in HHT1, 18.0% in HHT2, and 3.8% in HHT-negative controls). HHT2 and hepatic arteriovenous malformations (HAVMs) were the most important predictors for increased-probability PH (odds ratio 5.6, p = 0.002, and odds ratio 11.3, p < 0.001, respectively). Heritable pulmonary arterial hypertension (HPAH) was diagnosed in 2 patients (0.7%) and only found in HHT2 (1.3%).
CONCLUSION: The estimated prevalence of PH is higher in HHT patients compared to HHT-negative controls. This increase is especially present in HHT2 and mainly associated with the presence of HAVMs. HPAH appears to be rare in HHT patients and was only diagnosed in HHT2.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Echocardiography; Hereditary hemorrhagic telangiectasia; Heritable pulmonary arterial hypertension; Pulmonary hypertension

Mesh:

Year:  2017        PMID: 28743113     DOI: 10.1159/000458447

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  5 in total

1.  Severe pulmonary arterial hypertension in a patient with hereditary hemorrhagic telangiectasia and multiple pulmonary and hepatic arteriovenous malformations.

Authors:  Sunitha Aramalla; Srinivas Bhyravavajhala; Bharathi Vanaparty; Ramakrishna Narayanan; Sreekanth Yerram
Journal:  Ann Pediatr Cardiol       Date:  2022-06-14

2.  Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia Related to an ACVRL1 Mutation.

Authors:  Tetsuro Yokokawa; Koichi Sugimoto; Yusuke Kimishima; Tomofumi Misaka; Akiomi Yoshihisa; Hiroko Morisaki; Osamu Yamada; Kazuhiko Nakazato; Takafumi Ishida; Yasuchika Takeishi
Journal:  Intern Med       Date:  2019-09-11       Impact factor: 1.271

3.  Case Report: Clinical characteristics and genetic analysis of two patients with hereditary hemorrhagic telangiectasia.

Authors:  Qiu-Ying Wang; Yu-Xuan Feng; Ying-Wei Zhu; Yu-Xia Sun; Jing-Duan Xu; Hui-Min Shi; Yi-Min Mao; Hong-Wei Jiang
Journal:  Front Genet       Date:  2022-08-25       Impact factor: 4.772

Review 4.  Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia.

Authors:  Veronique M M Vorselaars; Anna E Hosman; Cornelis J J Westermann; Repke J Snijder; Johannes J Mager; Marie-Jose Goumans; Marco C Post
Journal:  Int J Mol Sci       Date:  2018-10-17       Impact factor: 5.923

Review 5.  TGF-β and BMPR2 Signaling in PAH: Two Black Sheep in One Family.

Authors:  Nina Rol; Konda Babu Kurakula; Chris Happé; Harm Jan Bogaard; Marie-José Goumans
Journal:  Int J Mol Sci       Date:  2018-08-31       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.